A survey of a COVID-19 cluster of charter flight importation.


Journal

Public health
ISSN: 1476-5616
Titre abrégé: Public Health
Pays: Netherlands
ID NLM: 0376507

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 08 05 2021
accepted: 03 09 2021
pubmed: 4 10 2021
medline: 28 10 2021
entrez: 3 10 2021
Statut: ppublish

Résumé

Although a number of cases of importation with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported, there are still no data available concerning the characteristics in the coronavirus disease 2019 (COVID-19) cluster of charter flight importation. Here, we provide an analysis of COVID-19 cases and their close contacts who worked for the same company on a project in Karbala, Iraq, and returned back to Chengdu, China, by a charter flight. The data of imported COVID-19 cases and their close contacts were obtained from National Notifiable Disease Report System of Chinese Center for Disease Control and Prevention and field epidemiological investigation reports by Centers for Disease Control and Prevention (CDCs) in Chengdu. The information of general characteristics and laboratory findings of this cluster were collected and summarized. One hundred and six (66.67%) of 159 charter flight passengers tested positive for COVID-19 before entry. Through treatment, all 159 people tested negative and meet the requirements of taking flights bound for China before boarding. However, there has been still 36 (22.64%) of them tested positive after entry. The median time from entry to confirmation was 1.0 day (Interquartile Range (IQR): 0-4.3). The Cycle threshold value (Ct value) of 36 patients' positive samples are all above 30 and most values are above 35. In conclusion, there is still a risk that a number of COVID-19 cases can be imported through charter flight. However, the infectivity of confirmed patients of the charter flight was considered to be low.

Identifiants

pubmed: 34601152
pii: S0033-3506(21)00351-6
doi: 10.1016/j.puhe.2021.09.004
pmc: PMC8435375
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107-109

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794447

Auteurs

Y Yue (Y)

Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, Sichuan, 610000, PR China; Chengdu Center for Disease Control and Prevention, Chengdu, Sichuan, 610000, PR China.

Y Chen (Y)

Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, Sichuan, 610000, PR China; Chengdu Center for Disease Control and Prevention, Chengdu, Sichuan, 610000, PR China.

X Du (X)

Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, Sichuan, 610000, PR China; Chengdu Center for Disease Control and Prevention, Chengdu, Sichuan, 610000, PR China.

Y Jin (Y)

Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, Sichuan, 610000, PR China; Dayi County Center for Disease Control and Prevention, Chengdu, Sichuan, 610000, PR China.

M Hu (M)

Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, Sichuan, 610000, PR China; Chengdu Center for Disease Control and Prevention, Chengdu, Sichuan, 610000, PR China.

X Jiang (X)

Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, Sichuan, 610000, PR China; Chengdu Center for Disease Control and Prevention, Chengdu, Sichuan, 610000, PR China.

C Wang (C)

Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, Sichuan, 610000, PR China; Chengdu Center for Disease Control and Prevention, Chengdu, Sichuan, 610000, PR China.

Z Chen (Z)

Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, Sichuan, 610000, PR China; Chengdu Center for Disease Control and Prevention, Chengdu, Sichuan, 610000, PR China.

L Su (L)

Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, Sichuan, 610000, PR China; Chengdu Center for Disease Control and Prevention, Chengdu, Sichuan, 610000, PR China.

C Chen (C)

Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, Sichuan, 610000, PR China; Chengdu Center for Disease Control and Prevention, Chengdu, Sichuan, 610000, PR China.

S Jiang (S)

Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, Sichuan, 610000, PR China; Chengdu Center for Disease Control and Prevention, Chengdu, Sichuan, 610000, PR China.

X Tuo (X)

Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, Sichuan, 610000, PR China; Chengdu Center for Disease Control and Prevention, Chengdu, Sichuan, 610000, PR China. Electronic address: 3439682@qq.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH